^
    1d
    PIVOT-006: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT (clinicaltrials.gov)
    P3, N=367, Active, not recruiting, CG Oncology, Inc. | Trial primary completion date: Jun 2026 --> Nov 2026
    Trial primary completion date
    |
    cretostimogene grenadenorepvec (CG0070)
    1d
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P4, N=50, Recruiting, Replimune Inc. | Phase classification: P --> P4
    Phase classification
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    2d
    Self-assembled manganese-based nanoplatforms synergizing immunogenic cell death and STING activation for triple-negative breast cancer. (PubMed, Mater Today Bio)
    In this study, we developed a manganese-based nanoparticle, termed HLM315, via one-step self-assembly of alendronate-modified hyaluronic acid (HA-AL), the amphiphilic cationic peptide LTX-315, and Mn2+ under weakly alkaline conditions. Ultimately, HLM315 systematically reshaped the TME and potently inhibited the tumor growth in TNBC orthotopic mouse model. Overall, HLM315 establishes a coordinated antitumor immune cascade and offers a promising strategy to enhance immunotherapy efficacy in TNBC.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    Oncopore (ruxotemitide)
    14d
    Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Enrolling by invitation, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    16d
    OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    Idafang (ivonescimab)
    16d
    OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    Idafang (ivonescimab)
    17d
    A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours. (clinicaltrials.gov)
    P1, N=18, Recruiting, Joint Biosciences Ltd.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    HR positive • MSI-H/dMMR • BRAF mutation • KRAS wild-type • RAS wild-type
    24d
    Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy. (PubMed, Clin Cancer Res)
    Sequential VCN-01 plus durvalumab was better tolerated than concomitant treatment. The recommended VCN-01 phase 2 dose (RP2D) was 1.0E13 vp, on the sequential schedule. Encouraging survival was observed in patients after progressing on anti-PD-(L)1 agents. Data supports VCN-01 replication associated with increased PD-1, PD-L1, and CD8 tumor expression. Sequential systemic delivery of VCN-01 and anti-PD-L1 therapy may represent an improved treatment for HNSCC.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)
    1m
    YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis. (PubMed, Int J Mol Sci)
    Here, we performed an integrative pan-cancer analysis across 53 independent datasets spanning 33 tumour types, incorporating transcriptomic (YBX1 mRNA), proteomic (RPPA), genomic, and clinical data...Elevated YB-1 protein levels were also associated with advanced disease stage and poorer survival outcomes and demonstrated a similar, although non-significant, directional trend with histologic grade. Collectively, these findings demonstrate that elevated YBX1 expression marks proliferative and clinically aggressive tumour states within which genomic instability-related features arise in a context-dependent manner, providing a clarified pan-cancer framework for interpreting YB-1-associated tumour biology.
    Journal • Tumor mutational burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • YBX1 (Y-Box Binding Protein 1)
    |
    HRD
    1m
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Recruiting, Clinica Universidad de Navarra, Universidad de Navarra | Active, not recruiting --> Recruiting
    Enrollment open
    |
    tasadenoturev (DNX-2401)
    2ms
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Clinica Universidad de Navarra, Universidad de Navarra | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    tasadenoturev (DNX-2401)
    2ms
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra
    Trial initiation date
    |
    tasadenoturev (DNX-2401)